Cardiovascular Safety of Testosterone-Replacement Therapy.

Aged Humans Male Middle Aged Cardiovascular Diseases / chemically induced Diabetes Mellitus, Type 2 Double-Blind Method Hypogonadism / blood Myocardial Infarction / epidemiology Stroke / epidemiology Testosterone / adverse effects Hormone Replacement Therapy / adverse effects Aged, 80 and over Gels Transdermal Patch

Journal

The New England journal of medicine

ISSN: 1533-4406

Titre abrégé: N Engl J Med

Pays: United States

ID NLM: 0255562

Informations de publication

Date de publication:
13 Jul 2023

Historique:

medline: 14 7 2023

pubmed: 16 6 2023

entrez: 16 6 2023

Statut: ppublish

Résumé

The cardiovascular safety of testosterone-replacement therapy in middle-aged and older men with hypogonadism has not been determined. In a multicenter, randomized, double-blind, placebo-controlled, noninferiority trial, we enrolled 5246 men 45 to 80 years of age who had preexisting or a high risk of cardiovascular disease and who reported symptoms of hypogonadism and had two fasting testosterone levels of less than 300 ng per deciliter. Patients were randomly assigned to receive daily transdermal 1.62% testosterone gel (dose adjusted to maintain testosterone levels between 350 and 750 ng per deciliter) or placebo gel. The primary cardiovascular safety end point was the first occurrence of any component of a composite of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke, assessed in a time-to-event analysis. A secondary cardiovascular end point was the first occurrence of any component of the composite of death from cardiovascular causes, nonfatal myocardial infarction, nonfatal stroke, or coronary revascularization, assessed in a time-to-event analysis. Noninferiority required an upper limit of less than 1.5 for the 95% confidence interval of the hazard ratio among patients receiving at least one dose of testosterone or placebo. The mean (±SD) duration of treatment was 21.7±14.1 months, and the mean follow-up was 33.0±12.1 months. A primary cardiovascular end-point event occurred in 182 patients (7.0%) in the testosterone group and in 190 patients (7.3%) in the placebo group (hazard ratio, 0.96; 95% confidence interval, 0.78 to 1.17; P<0.001 for noninferiority). Similar findings were observed in sensitivity analyses in which data on events were censored at various times after discontinuation of testosterone or placebo. The incidence of secondary end-point events or of each of the events of the composite primary cardiovascular end point appeared to be similar in the two groups. A higher incidence of atrial fibrillation, of acute kidney injury, and of pulmonary embolism was observed in the testosterone group. In men with hypogonadism and preexisting or a high risk of cardiovascular disease, testosterone-replacement therapy was noninferior to placebo with respect to the incidence of major adverse cardiac events. (Funded by AbbVie and others; TRAVERSE ClinicalTrials.gov number, NCT03518034.).

Sections du résumé

BACKGROUND BACKGROUND

The cardiovascular safety of testosterone-replacement therapy in middle-aged and older men with hypogonadism has not been determined.

METHODS METHODS

In a multicenter, randomized, double-blind, placebo-controlled, noninferiority trial, we enrolled 5246 men 45 to 80 years of age who had preexisting or a high risk of cardiovascular disease and who reported symptoms of hypogonadism and had two fasting testosterone levels of less than 300 ng per deciliter. Patients were randomly assigned to receive daily transdermal 1.62% testosterone gel (dose adjusted to maintain testosterone levels between 350 and 750 ng per deciliter) or placebo gel. The primary cardiovascular safety end point was the first occurrence of any component of a composite of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke, assessed in a time-to-event analysis. A secondary cardiovascular end point was the first occurrence of any component of the composite of death from cardiovascular causes, nonfatal myocardial infarction, nonfatal stroke, or coronary revascularization, assessed in a time-to-event analysis. Noninferiority required an upper limit of less than 1.5 for the 95% confidence interval of the hazard ratio among patients receiving at least one dose of testosterone or placebo.

RESULTS RESULTS

The mean (±SD) duration of treatment was 21.7±14.1 months, and the mean follow-up was 33.0±12.1 months. A primary cardiovascular end-point event occurred in 182 patients (7.0%) in the testosterone group and in 190 patients (7.3%) in the placebo group (hazard ratio, 0.96; 95% confidence interval, 0.78 to 1.17; P<0.001 for noninferiority). Similar findings were observed in sensitivity analyses in which data on events were censored at various times after discontinuation of testosterone or placebo. The incidence of secondary end-point events or of each of the events of the composite primary cardiovascular end point appeared to be similar in the two groups. A higher incidence of atrial fibrillation, of acute kidney injury, and of pulmonary embolism was observed in the testosterone group.

CONCLUSIONS CONCLUSIONS

In men with hypogonadism and preexisting or a high risk of cardiovascular disease, testosterone-replacement therapy was noninferior to placebo with respect to the incidence of major adverse cardiac events. (Funded by AbbVie and others; TRAVERSE ClinicalTrials.gov number, NCT03518034.).

Identifiants

DOI: 10.1056/NEJMoa2215025 PMID: 37326322

pubmed: 37326322

doi: 10.1056/NEJMoa2215025

doi:

Substances chimiques

Testosterone 3XMK78S47O

Gels 0

Banques de données

ClinicalTrials.gov

['NCT03518034']

Types de publication

Equivalence Trial Journal Article Multicenter Study Randomized Controlled Trial

Langues

eng

Sous-ensembles de citation

Pagination

107-117

Investigateurs

R Helm (R)

P Trueba (P)

S Kester (S)

S Ansari (S)

A Makhlouf (A)

V Hoon (V)

S Aslam (S)

K Bender (K)

J Cardona (J)

A Dinnerstein (A)

B Wieskopf (B)

R Falcone (R)

J Mandry (J)

E Shapiro (E)

M Darani (M)

L Pearlman (L)

S Nasir (S)

R Heller (R)

J Miracle (J)

M Digiovanna (M)

K Lucas (K)

N Andrawis (N)

E Davidson (E)

M Doty (M)

D Mishkin (D)

C Brinson (C)

N Farris (N)

G Kipp (G)

A Krishna (A)

P Moore (P)

G Yeoman (G)

M Allaw (M)

J Bashour (J)

R Montgomery (R)

A Tan (A)

A Ahmad (A)

D Levinson (D)

G Shockey (G)

K Ayesu (K)

L McGill (L)

N Secrist (N)

N Gabra (N)

J Kopp (J)

N Morrar (N)

R Powell (R)

R Severance (R)

P Bravo (P)

R Broughton (R)

K Cruz (K)

S Gorrela (S)

B MacGillivray (B)

J Loy (J)

C Lunn (C)

T Gilford (T)

P Grossman (P)

T Howard (T)

A Mendelson (A)

E Riffer (E)

C Calinescu (C)

P Levins (P)

R Strzinek (R)

F Velazquez (F)

M Billings (M)

G Debs-Perez (G)

K Lee (K)

I Marar (I)

R Toma (R)

A Adams (A)

H Audish (H)

M Azizad (M)

C Greiwe (C)

A L Lewy-Alterbaum (AL)

L Akright (L)

A Al-Karadsheh (A)

J DeGrauw (J)

S Dua (S)

W Jennings (W)

L Odekirk (L)

M Trevino (M)

J Venereo (J)

M Agha (M)

S Benjamin (S)

M Efros (M)

J C Garza (JC)

V Gold (V)

J Kay (J)

L Rudolph (L)

A Fatakia (A)

M Goisse (M)

A Hartman (A)

K Vora (K)

A Bhargava (A)

L Murray (L)

T Pluto (T)

V Fragoso (V)

S Geller (S)

M Lopez (M)

R Orr (R)

W Patton (W)

B Seidman (B)

L Thurman (L)

H Tran (H)

M Winnie (M)

D Allison (D)

P Nugent (P)

L Nunez (L)

M Nunez (M)

G Quesada (G)

J Solis (J)

N Wick (N)

J Andersen (J)

W Bowman (W)

D Butuk (D)

L Connery (L)

G Freeman (G)

M Janik (M)

R Klein (R)

R Lending (R)

T Lenzmeier (T)

J Sandberg (J)

P Wylie (P)

N Azad (N)

A Barber (A)

S Bauer (S)

H Maheshwari (H)

F Munoz (F)

K Soe (K)

E Soroka (E)

H Upadhyay (H)

J Agaiby (J)

C Bird (C)

G Disick (G)

L Duke (L)

T Gaskin (T)

N Godbole (N)

R Huling (R)

D Jack (D)

W Knapp (W)

G Ledesma (G)

S Makam (S)

S A Mujica Trenche (SA)

J Schmidt (J)

L Tharenos (L)

S Wilson (S)

R Anderson (R)

K Barbel-Johnson (K)

P Barnhill (P)

D Bouda (D)

J Daniel (J)

L Feld (L)

T Fiel (T)

S Grubb (S)

M Hummel (M)

S Koch (S)

M Kramer (M)

J Pouzar (J)

G Trullenque (G)

M Welch (M)

E Armas (E)

J Chang (J)

R Jordan (R)

S Leichter (S)

R Perry (R)

W Randall (W)

R Sastre (R)

E Bolster (E)

A Cohen (A)

C Griffin (C)

C Herman (C)

J Jacqmein (J)

B Khan (B)

I Lieber (I)

C Mbogua (C)

A Murcia (A)

R Patel (R)

H Stamps (H)

R Swerdloff (R)

J Whatley (J)

M Adams (M)

J Bailen (J)

M Bidair (M)

C Breton (C)

N Daboul (N)

G Flippo (G)

M Franco (M)

G Funk (G)

E Gaddam (E)

T Hart (T)

D Headley (D)

D James (D)

D Koontz (D)

D McNeil (D)

M Raikhel (M)

M Cornett (M)

A Daluga (A)

R D'Anna (R)

A Gosmanov (A)

A Iranmanesh (A)

A Qureshi (A)

H Reyes (H)

S Rosenberg (S)

D Spiller (D)

R Estevez (R)

B Green (B)

E Hanna (E)

R Kastelic (R)

M Lawrence (M)

R Manning (R)

K Maynard (K)

C Ng (C)

L Phillips (L)

S Plantholt (S)

O Ruffin (O)

J Walsh (J)

M Woolman (M)

S Arora (S)

V Awasty (V)

T Barker (T)

S Butman (S)

D Cahn (D)

S Dhindsa (S)

A Doshi (A)

A Drabick (A)

R Hood (R)

M Jardula (M)

J Kovac (J)

D McMullen (D)

W Pharr (W)

S Phatak (S)

L Quintero (L)

A Becker (A)

B Christine (B)

W Fitzgibbons (W)

D Fitz-Patrick (D)

N Fraser (N)

B Gilbert (B)

I Goldstein (I)

J Haffizulla (J)

J Lillo (J)

T Nguyen (T)

E Riley (E)

D Storey (D)

S Tebi (S)

D Uba (D)

J Wayne (J)

D Ajani (D)

E Christofides (E)

D Francyk (D)

D Huffman (D)

S Malempati (S)

A Odugbesan (A)

B Pierpont (B)

M Rausch (M)

N Razzaque (N)

K Rictor (K)

J Stewart (J)

D Tripathy (D)

T Briskin (T)

K Cohen (K)

A Dang (A)

K Fox (K)

S Freedman (S)

A George (A)

E Goldfischer (E)

R Hollister (R)

R Jacks (R)

K Kelley (K)

R Mills (R)

R Mohseni (R)

F Saba (F)

J Sensenbrenner (J)

E Sorial (E)

P Wakefield (P)

L Whitlock (L)

M Ampajwala (M)

J Borders (J)

P Bradley (P)

O G Brkic-Vukotic (OG)

A Brockmyre (A)

J Chehade (J)

R Harris (R)

N Jaffrani (N)

J Kaminetsky (J)

G Ledger (G)

S Lerman (S)

A Mabaquiao (A)

I J Madu (IJ)

R Myers (R)

S Nakhle (S)

J Perez (J)

W Rust (W)

J Serje (J)

L Smith (L)

M Tellez (M)

L Belkoff (L)

L Berman (L)

J Cochran (J)

C Cone (C)

K Ellis (K)

S M Harman (SM)

L Herman (L)

J Kirby (J)

D Liljenquist (D)

E Morawski (E)

N C Morcos (NC)

M Patel (M)

W Penny (W)

E Portnoy (E)

M Shanik (M)

H Bagga (H)

V Bland (V)

P Bressler (P)

J Condit (J)

A Latorre (A)

R Leon (R)

M Marcelli (M)

M Palatnik (M)

B Rizzardi (B)

M Vaughn (M)

J Vazquez-Tanus (J)

J Willis (J)

A Alcantara (A)

K Blaze (K)

W Clark (W)

G Cortes-Maisonet (G)

T Dixon (T)

P Greenberg (P)

A Gupta (A)

C Harper (C)

H Kerr (H)

R Leggett (R)

E Levin (E)

V Mahabadi (V)

B Miranda (B)

J H Peniston (JH)

A Seftel (A)

N Sunkara (N)

A Wokhlu (A)

B Wolf (B)

D Wynn (D)

R Adler (R)

O Barnum (O)

A Clark (A)

D Cohen-Neamie (D)

A Comulada Rivera (A)

B Cowan (B)

M Dawson (M)

A Dobs (A)

J Elsen (J)

B Essink (B)

R Farsad (R)

B First (B)

B Frandsen (B)

A Frisoli (A)

N Gabrail (N)

R Garcia (R)

S Georgeson (S)

J Gilbert (J)

L Hernandez-Vazquez (L)

A Hoffman (A)

R Hunter (R)

D Hurley (D)

L Jenkins (L)

A Kabour (A)

D Kayne (D)

Y Kidokoro (Y)

D Lee (D)

A Matsumoto (A)

A Mills (A)

D Mobley (D)

S P Mokshagundam (SP)

M Pahor (M)

B Purushottam (B)

O Raheem (O)

S Randhawa (S)

S Shah (S)

M Syed (M)

S Thomson (S)

L Torres (L)

Steven E Nissen (SE)

A Michael Lincoff (AM)

Shalender Bhasin (S)

Shehzad Basaria (S)

William E Boden (WE)

Glen R Cunningham (GR)

Christopher B Granger (CB)

Mohit Khera (M)

Ian M Thompson (IM)

Venu Menon (V)

Vidysagar Kalahasti (V)

Lisa M Mitchell (LM)

Kathy Wolski (K)

Qiuqing Wang (Q)

Deborah Davey (D)

Michelle Garcia (M)

Kimberly J Brown (KJ)

Robin Rodriguez (R)

Craig Balog (C)

Julie St John (JS)

Tamera Gamble (T)

Michael G Miller (MG)

Panagiotis Flevaris (P)

Michael C Snabes (MC)

Anna Chan (A)

Elena Dubcenco (E)

Xue Li (X)

Tingting Yi (T)

Biden Huang (B)

Teri Pannesi (T)

Brage Garofalo (B)

Rachel A Preuss (RA)

Samantha J Phillips (SJ)

Anne Shover (A)

Sheryn Bruso (S)

Tasneem Poonawala (T)

Nader S Khan (NS)

Fatima D Khan (FD)

Sandra Fukumoto (S)

Liangrui Sun (L)

Thomas J Korellis (TJ)

Culley Carson (C)

Adrian Dobs (A)

Alvin M Matsumoto (AM)

Peter Snyder (P)

John R Teerlink (JR)

John H Alexander (JH)

William Bremner (W)

Eric Klein (E)

Darren K McGuire (DK)

Janet Wittes (J)

D Renato (D)

D Lopes (D)

Andrew Armstrong (A)

Kevin A Buhr (KA)

Peter Hu (P)

David Nemer (D)

Divyang Patel (D)

Joshua Parker (J)

Nabil Sabbak (N)

Jitendra Sharma (J)

Michael P O'Leary (MP)

Mark A Preston (MA)

Douglas C Bauer (DC)

Bo Fan (B)

Karol M Pencina (KM)

Thomas G Travison (TG)

Michael O'Leary (M)

Lauren Lauren (L)

Shein Nanji (S)

Alicia Bush (A)

Gopi Patel (G)

Richa Chhibber (R)

Jennifer Potter (J)

S Prem Sankar (SP)

Miriam Garduno Aguirre (M)

Jamaal Ali (J)

Sally Stephens (S)

Lindsey Sattler (L)

Diane Getsy Palmer (D)

Renee Sullivan (R)

Jamie Wantock (J)

Laura Gelpke (L)

Rosemary Molinari (R)

Commentaires et corrections

Type : CommentIn